We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.62B
1-Year Est. Return 138.67%
This Fund
S&P 500
This Quarter Est. Return
+19.33%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.3B
AUM Growth
+$8.08M
Cap. Flow
-$150M
Cap. Flow %
-11.5%
Top 10 Hldgs %
81.52%
Holding
28
New
2
Increased
17
Reduced
5
Closed
3

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$60.2M
2
BEAM icon
Beam Therapeutics
BEAM
+$33.6M
3
PCVX icon
Vaxcyte
PCVX
+$25.8M
4
LQDA icon
Liquidia Corp
LQDA
+$14.7M
5
DVAX
Dynavax Technologies
DVAX
+$13.8M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$13.9M
2
TVTX icon
Travere Therapeutics
TVTX
+$6.77M
3
TYRA icon
Tyra Biosciences
TYRA
+$2.07M
4
COGT icon
Cogent Biosciences
COGT
+$201K

Sector Composition

Rank Sector Weight
1 Healthcare 98.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
26
PUT
Alnylam Pharmaceuticals
ALNY
$36.3B
– –
-43,000
Closed -$10.4M
INSM icon
27
CALL
Insmed
INSM
$23.2B
– –
-1,000,000
Closed -$67M
SPY icon
28
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
– –
-200,000
Closed -$109M
1
2

Similar funds

IPW
Invictus Private Wealth Denver, Colorado $1.62B AUM 22.63% 1-Year Est. Return
WIC
Woodmont Investment Counsel Nashville, Tennessee $1.62B AUM 18.92% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
TLFA
True Link Financial Advisors San Francisco, California $1.62B AUM 8.33% 1-Year Est. Return
KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
PRA
Pine Ridge Advisers New York $1.62B AUM 16.97% 1-Year Est. Return
BW
Browning West Los Angeles, California $1.62B AUM 22.28% 1-Year Est. Return
CC
Covalis Capital London, United Kingdom $1.63B AUM 27.84% 1-Year Est. Return

Kynam Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Kynam Capital Management held 28 positions worth $1.3B, up 0.62% from $1.3B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Kynam Capital Management withdrew a net $150M in Q3 2024, closing 3 positions and reducing 5 holdings. Its largest reduction was Protagonist Therapeutics, cutting an estimated $13.9M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 74% a quarter earlier.

Against the trend, Kynam Capital Management opened a new position in Beam Therapeutics worth $31.9M.

  • Kynam Capital Management's largest Q3 2024 buy was Beam Therapeutics: 1,302,085 shares worth $31.9M.
  • Kynam Capital Management added most to CG Oncology in Q3 2024, an estimated $60.2M increase.
  • Kynam Capital Management's biggest Q3 2024 reduction was Protagonist Therapeutics, cutting an estimated $13.9M.
  • Kynam Capital Management's ten largest holdings make up 82% of its $1.3B portfolio in Q3 2024.
  • Kynam Capital Management opened 2 new positions and closed 3 in Q3 2024.
  • Kynam Capital Management's portfolio value rose 0.62% quarter-over-quarter to $1.3B.

Based on Kynam Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.